ARTICLE | Clinical News
Oral omecamtiv mercabil: Ph III started
December 2, 2016 9:49 PM UTC
Cytokinetics said Amgen began the double-blind, placebo-controlled, international Phase III GALACTIC-HF Phase III trial to evaluate oral omecamtiv mecarbil titrated to doses of up to 50 mg twice daily...
BCIQ Target Profiles